SG11201811100RA - Treatment of retinal vascular disease using progenitor cells - Google Patents
Treatment of retinal vascular disease using progenitor cellsInfo
- Publication number
- SG11201811100RA SG11201811100RA SG11201811100RA SG11201811100RA SG11201811100RA SG 11201811100R A SG11201811100R A SG 11201811100RA SG 11201811100R A SG11201811100R A SG 11201811100RA SG 11201811100R A SG11201811100R A SG 11201811100RA SG 11201811100R A SG11201811100R A SG 11201811100RA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- johnson
- rule
- pennsylvania
- applicant
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/48—Reproductive organs
- A61K35/51—Umbilical cord; Umbilical cord blood; Umbilical stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0603—Embryonic cells ; Embryoid bodies
- C12N5/0605—Cells from extra-embryonic tissues, e.g. placenta, amnion, yolk sac, Wharton's jelly
Abstract
INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 11 January 2018 (11.01.2018) W I PO I PCT omit n OH 10 0 011101101111 OM IMMO 011 (10) International Publication Number WO 2018/009385 Al (51) International Patent Classification: A61K 35/51 (2015.01) A61P 27/02 (2006.01) (21) International Application Number: PCT/US2017/039660 (22) International Filing Date: 28 June 2017 (28.06.2017) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/358,389 05 July 2016 (05.07.2016) US (71) Applicant: JANSSEN BIOTECH, INC. [US/US]; 800/850 Ridgeview Drive, Horsham, Pennsylvania 19044 (US). (72) Inventors: HARRIS, Ian; 1400 McKean Road, Spring House, Pennsylvania 19477 (US). DEJNEKA, Nadine Sophia; 1400 McKean Road, Spring House, Pennsylvania 19477 (US). (74) Agent: SHIRTZ, Joseph F. et al.; JOHNSON & JOHNSON, One Johnson & Johnson Plaza, New Brunswick, New Jersey 08933 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: — with international search report (Art. 21(3)) with sequence listing part of description (Rule 5.2(a)) Declarations under Rule 4.17: as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii)) pp 11 as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii)) O 00 (54) Title: TREATMENT OF RETINAL VASCULAR DISEASE USING PROGENITOR CELLS 1-1 0 (57) : Methods and compositions for treating ophthalmic disease, reducing retinal neovascularization and retinal vascular \" leakage using progenitor cells, such as postpartum-derived cells, and conditioned media from the cells, are disclosed.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662358389P | 2016-07-05 | 2016-07-05 | |
PCT/US2017/039660 WO2018009385A1 (en) | 2016-07-05 | 2017-06-28 | Treatment of retinal vascular disease using progenitor cells |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201811100RA true SG11201811100RA (en) | 2019-01-30 |
Family
ID=59363222
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201811100RA SG11201811100RA (en) | 2016-07-05 | 2017-06-28 | Treatment of retinal vascular disease using progenitor cells |
Country Status (16)
Country | Link |
---|---|
US (1) | US20180015129A1 (en) |
EP (1) | EP3481405A1 (en) |
JP (1) | JP2019524688A (en) |
KR (1) | KR20190026758A (en) |
CN (1) | CN109414460A (en) |
AR (1) | AR108972A1 (en) |
AU (1) | AU2017291707A1 (en) |
BR (1) | BR112019000059A2 (en) |
CA (1) | CA3029997A1 (en) |
MA (1) | MA45623A (en) |
MX (1) | MX2019000050A (en) |
PH (1) | PH12018502704A1 (en) |
RU (1) | RU2019102933A (en) |
SG (1) | SG11201811100RA (en) |
TW (1) | TW201811344A (en) |
WO (1) | WO2018009385A1 (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114712393B (en) * | 2020-12-18 | 2024-01-19 | 中国人民解放军海军军医大学第三附属医院 | Application of Hnf-1 alpha gene modified mesenchymal stem cells in preventing and treating liver cancer |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5707643A (en) | 1993-02-26 | 1998-01-13 | Santen Pharmaceutical Co., Ltd. | Biodegradable scleral plug |
US5466233A (en) | 1994-04-25 | 1995-11-14 | Escalon Ophthalmics, Inc. | Tack for intraocular drug delivery and method for inserting and removing same |
US5725493A (en) | 1994-12-12 | 1998-03-10 | Avery; Robert Logan | Intravitreal medicine delivery |
US5718922A (en) | 1995-05-31 | 1998-02-17 | Schepens Eye Research Institute, Inc. | Intravitreal microsphere drug delivery and method of preparation |
US5869079A (en) | 1995-06-02 | 1999-02-09 | Oculex Pharmaceuticals, Inc. | Formulation for controlled release of drugs by combining hydrophilic and hydrophobic agents |
US5902598A (en) | 1997-08-28 | 1999-05-11 | Control Delivery Systems, Inc. | Sustained release drug delivery devices |
CA2370330C (en) | 1999-04-16 | 2009-01-20 | Wm. Marsh Rice University | Biodegradable poly(propylene fumarate) networks cross linked with poly(propylene fumarate)-diacrylate macromers |
US6355699B1 (en) | 1999-06-30 | 2002-03-12 | Ethicon, Inc. | Process for manufacturing biomedical foams |
US6555374B1 (en) | 1999-08-19 | 2003-04-29 | Artecel Sciences, Inc. | Multiple mesodermal lineage differentiation potentials for adipose tissue-derived stromal cells and uses thereof |
US6331313B1 (en) | 1999-10-22 | 2001-12-18 | Oculex Pharmaceticals, Inc. | Controlled-release biocompatible ocular drug delivery implant devices and methods |
US6375972B1 (en) | 2000-04-26 | 2002-04-23 | Control Delivery Systems, Inc. | Sustained release drug delivery devices, methods of use, and methods of manufacturing thereof |
US9969980B2 (en) | 2001-09-21 | 2018-05-15 | Garnet Biotherapeutics | Cell populations which co-express CD49c and CD90 |
ES2564045T3 (en) | 2003-06-27 | 2016-03-17 | DePuy Synthes Products, Inc. | Postpartum derived cells for use in the treatment of heart disease and the circulatory system |
US8790637B2 (en) | 2003-06-27 | 2014-07-29 | DePuy Synthes Products, LLC | Repair and regeneration of ocular tissue using postpartum-derived cells |
SG170789A1 (en) * | 2005-12-28 | 2011-05-30 | Ethicon Inc | Treatment of peripheral vascular disease using postpartum-derived cells |
-
2017
- 2017-06-28 EP EP17740522.2A patent/EP3481405A1/en not_active Withdrawn
- 2017-06-28 CN CN201780041905.5A patent/CN109414460A/en active Pending
- 2017-06-28 US US15/636,140 patent/US20180015129A1/en not_active Abandoned
- 2017-06-28 MA MA045623A patent/MA45623A/en unknown
- 2017-06-28 BR BR112019000059A patent/BR112019000059A2/en not_active IP Right Cessation
- 2017-06-28 SG SG11201811100RA patent/SG11201811100RA/en unknown
- 2017-06-28 MX MX2019000050A patent/MX2019000050A/en unknown
- 2017-06-28 RU RU2019102933A patent/RU2019102933A/en not_active Application Discontinuation
- 2017-06-28 JP JP2018568884A patent/JP2019524688A/en active Pending
- 2017-06-28 KR KR1020197001133A patent/KR20190026758A/en unknown
- 2017-06-28 WO PCT/US2017/039660 patent/WO2018009385A1/en unknown
- 2017-06-28 CA CA3029997A patent/CA3029997A1/en not_active Abandoned
- 2017-06-28 AU AU2017291707A patent/AU2017291707A1/en not_active Abandoned
- 2017-07-03 TW TW106122179A patent/TW201811344A/en unknown
- 2017-07-05 AR ARP170101862A patent/AR108972A1/en unknown
-
2018
- 2018-12-20 PH PH12018502704A patent/PH12018502704A1/en unknown
Also Published As
Publication number | Publication date |
---|---|
AR108972A1 (en) | 2018-10-17 |
AU2017291707A1 (en) | 2019-01-03 |
US20180015129A1 (en) | 2018-01-18 |
BR112019000059A2 (en) | 2019-10-01 |
MA45623A (en) | 2019-05-15 |
CN109414460A (en) | 2019-03-01 |
RU2019102933A (en) | 2020-08-05 |
JP2019524688A (en) | 2019-09-05 |
KR20190026758A (en) | 2019-03-13 |
WO2018009385A1 (en) | 2018-01-11 |
TW201811344A (en) | 2018-04-01 |
PH12018502704A1 (en) | 2019-11-11 |
EP3481405A1 (en) | 2019-05-15 |
MX2019000050A (en) | 2019-05-02 |
CA3029997A1 (en) | 2018-01-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG11201900163PA (en) | Macrocycle kinase inhibitors | |
SG11201805044WA (en) | Compounds useful as kinase inhibitors | |
SG11201909949XA (en) | Targeted immunotolerance | |
SG11201811432WA (en) | Rna for cancer therapy | |
SG11201804373VA (en) | Compositions and methods for immunooncology | |
SG11201906386XA (en) | Combination therapy involving diaryl macrocyclic compounds | |
SG11201811470PA (en) | Pyrazolopyrimidine derivatives as kinase inhibitor | |
SG11201811431VA (en) | Multispecific antibodies against cd40 and cd137 | |
SG11201407580YA (en) | Composition comprising two antibodies engineered to have reduced and increased effector function | |
SG11201810579YA (en) | Pyrimidin-2-ylamino-1h-pyrazols as lrrk2 inhibitors for use in the treatment of neurodegenerative disorders | |
SG11201808222RA (en) | Methods of treatment of cholestatic diseases | |
SG11201810280YA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
SG11201810628XA (en) | Nasal pharmaceutical compositions with a porous excipient | |
SG11201809751XA (en) | Egfr inhibitor compounds | |
SG11201805001UA (en) | Method of treating influenza a | |
SG11201909680UA (en) | Phenyl-2-hydroxy-acetylamino-2-methyl-phenyl compounds | |
SG11201900551WA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
SG11201900546UA (en) | Spiro-lactam and bis-spiro-lactam nmda receptor modulators and uses thereof | |
SG11201810965YA (en) | 1h-pyrazolo[4,3-b]pyridines as pde1 inhibitors | |
SG11201903061YA (en) | Combination treatments comprising administration of imidazopyrazinones | |
SG11201804704PA (en) | Compositions and methods for decreasing tau expression | |
SG11201805311XA (en) | Method of treating a mammal, including human, against cancer using methionine and asparagine depletion | |
SG11201900361RA (en) | Methods of treating prostate cancer | |
SG11201901534VA (en) | Combination therapy with controlled-release cnp agonists | |
SG11201807523PA (en) | Ilt7 binding molecules and methods of using the same |